Mettler Toledo Financial Model
Laboratory Equipment Company Financials Example (Free Excel Download)
Mettler Toledo is a global manufacturer of precision instruments and services for use in laboratory, industrial, and food retailing applications.
professionals from Deloitte
Used by professionals from
About this model
This model projects Mettler-Toledo International Inc.'s (MTD) three-statement financials and free cash flow to determine its intrinsic equity valuation and assess the sustainability of its aggressive share repurchase programme.
Mettler Toledo is a global manufacturer of precision instruments and services for use in laboratory, industrial, and food retailing applications. The company operates a highly profitable, asset-light business model with a significant recurring revenue stream from its global service network. Business segments:
- Laboratory Instruments (approx. 56% of revenue)
- Industrial Instruments (approx. 39% of revenue)
- Retail Weighing Solutions (approx. 5% of revenue)
Key geographies include the Americas (42%), Europe (29%), and Asia/Rest of World (29%). The company holds the global number-one market position in most of its product categories, benefiting from high switching costs and a massive installed base that drives recurring service revenue (which accounts for approximately 25% of total sales).
The downloadable Mettler Toledo financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsMettler Toledo financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.72B | $3.92B | $3.79B | $3.87B | $4.03B |
| Gross profit | $2.17B | $2.31B | $2.24B | $2.33B | $2.39B |
| Research and development | $169.8M | $177.1M | $185.3M | $189.4M | $199.4M |
| Net income | $769.0M | $872.5M | $788.8M | $863.1M | $869.2M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Mettler Toledo
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Laboratory Instruments
- Segment name: Laboratory Instruments
- Revenue driver formula: Laboratory Volume Growth x Realised Pricing + Service Attachment Revenue
- Historical growth rate: 4% to 7% CAGR
- Key growth levers and headwinds: Bioproduction growth, pharmaceutical R&D spending, and automation trends; headwinds include biotech funding slowdowns and academic budget constraints.
- Pricing dynamics: High pricing power due to the critical nature of precision measurement in compliance and quality control.
- Revenue recognition notes: Equipment sales recognised upon delivery; service contracts deferred and recognised over the contract term.
- Seasonality: Q4 is historically the strongest quarter due to year-end budget flushes in corporate and academic labs.
Industrial Instruments
- Segment name: Industrial Instruments
- Revenue driver formula: Industrial Volume Growth x Realised Pricing + Service Attachment Revenue
- Historical growth rate: 3% to 5% CAGR
- Key growth levers and headwinds: Supply chain automation, logistics investments, and product inspection needs; headwinds include global manufacturing PMIs and macroeconomic slowdowns.
- Pricing dynamics: Value-based pricing tied to efficiency gains and waste reduction for manufacturers.
- Revenue recognition notes: Standard equipment recognised upon delivery; complex integrated systems may use percentage-of-completion.
- Seasonality: Less pronounced than the laboratory segment, but generally stronger in the second half of the year.
Retail Weighing Solutions
- Segment name: Retail Weighing Solutions
- Revenue driver formula: Retail Volume Growth x Realised Pricing + Service Attachment Revenue
- Historical growth rate: 0% to 2% CAGR
- Key growth levers and headwinds: Supermarket upgrades and networked scale adoption; headwinds include grocery margin pressures and long replacement cycles.
- Pricing dynamics: Highly competitive market with lower pricing power compared to laboratory instruments.
- Revenue recognition notes: Recognised upon delivery and installation.
- Seasonality: Q3 and Q4 are typically stronger ahead of the holiday shopping season.
Cost Structure
Variable Costs / COGS
- COGS includes raw materials, manufacturing overhead, direct labour, tariff costs, and service personnel expenses.
- Gross margin range: 58.0% to 60.5% (59.4% in 2025).
- Key input costs: Electronic components, metals, and global freight.
- How COGS scales with revenue: High gross margins mean incremental volume drops cleanly to the bottom line, though recent tariff increases have pressured margins slightly.
Operating Expenses
- R&D: Typically 4.5% to 5.0% of revenue, focused on software (LabX), automation, and digital sensors.
- SG&A: Typically 25.0% to 26.5% of revenue, heavily driven by the massive direct sales and service workforce (approx. 9,300 employees).
- Depreciation & Amortisation: Low, typically 3.0% to 4.0% of revenue, reflecting the asset-light assembly nature of the business.
- Stock-Based Compensation: Approx. 1.0% to 1.5% of revenue.
- Restructuring / one-time charges: Infrequent, usually minor footprint consolidations.
Margin Profile
- Gross margin: 58.0% to 60.5%
- EBITDA margin: 31.0% to 33.0%
- Operating margin: 29.0% to 31.0% (29.6% adjusted in 2025)
- Net margin: 21.0% to 23.0%
- Margin trend: Historically expanding due to pricing power and mix shift towards higher-margin service revenue, though temporarily compressed in 2025 due to tariffs.
Balance Sheet Structure
- Total assets: Approx. $3.5 billion to $4.0 billion.
- Key asset categories: Cash, accounts receivable, inventory, and goodwill.
- Goodwill & intangibles: Represent a moderate portion of assets due to historical bolt-on acquisitions (e.g., PendoTECH).
- Working capital profile:
- Days Sales Outstanding (DSO): 35 to 45 days.
- Days Inventory Outstanding (DIO): 40 to 50 days.
- Days Payable Outstanding (DPO): 35 to 45 days.
- Net working capital as % of revenue: Very low, often operating near zero or slightly negative, allowing the company to fund growth internally.
- PP&E: Approx. $800 million, primarily final assembly and testing facilities.
- Right-of-use assets / operating leases: Moderate, related to leased sales offices and service centres globally.
Capital Expenditure & Investment
- Capex as % of revenue: 2.5% to 3.5% (highly asset-light).
- Maintenance capex vs. growth capex: Roughly 50/50 split, with growth capex focused on IT infrastructure, software development, and facility automation.
- Major capex programmes: Smart Manufacturing approaches and global process standardisation (Blue Ocean).
- Capitalised software: Material due to internal use software and customer-facing platforms like LabX.
- M&A pattern: Occasional bolt-on acquisitions to acquire niche technologies.
Debt & Capital Structure
- Total debt: Approx. $2.3 billion.
- Net debt: Approx. $2.2 billion (cash balances are kept minimal).
- Debt/EBITDA ratio: 1.5x to 2.0x (conservative leverage).
- Key debt instruments: Senior notes and a revolving credit facility.
- Maturity profile: Well-laddered senior notes.
- Interest rate profile: Mix of fixed-rate notes and floating-rate bank debt.
- Share repurchase programme: Extremely active. The company uses almost 100% of its free cash flow to buy back shares, consistently reducing share count by 2% to 4% annually.
- Dividend policy: The company does not pay a dividend.
Cash Flow Characteristics
- Operating cash flow conversion: Consistently >100% of net income due to high non-cash charges and tight working capital management.
- Free cash flow margin: 21.0% to 24.0% of revenue ($878 million in 2025).
- Major non-cash items: Depreciation, amortisation, and stock-based compensation.
- Working capital cash flow impact: Generally neutral to a slight source of cash.
- Capex intensity: Very low.
- Cash tax rate vs. GAAP effective tax rate: Often lower than the statutory rate due to discrete tax benefits from stock option exercises and Swiss tax structures.
Sheet Structure
- Assumptions: Hardcoded drivers for macroeconomic inputs, segment growth rates, margin targets, and capital allocation policies.
- Revenue_Build: Revenue projected separately for Laboratory Instruments, Industrial Instruments, and Retail Weighing Solutions.
- Income_Statement: Consolidated P&L from Revenue down to Net Income and EPS, mirroring the 10-K format.
- Balance_Sheet: Assets, Liabilities, and Shareholders' Equity.
- Cash_Flow_Statement: Operating, Investing, and Financing cash flows, highlighting the massive share repurchase line item.
- Working_Capital: Schedules for Accounts Receivable, Inventory, Accounts Payable, and Deferred Revenue.
- Debt_and_Interest: Tranches of senior notes, revolver drawdowns, and interest expense calculations.
- Depreciation_Amortisation: PP&E roll-forward, intangible asset amortisation, and capex schedules.
- Shareholders_Equity: Retained earnings roll-forward and treasury stock tracking (critical for MTD due to buybacks).
- DCF_Valuation: Unlevered free cash flow calculation, WACC build-up, terminal value, and implied share price.
Key Financial Relationships
- Laboratory Revenue = Prior Year Laboratory Revenue x (1 + Laboratory Growth Rate)
- Industrial Revenue = Prior Year Industrial Revenue x (1 + Industrial Growth Rate)
- Retail Revenue = Prior Year Retail Revenue x (1 + Retail Growth Rate)
- Total Revenue = Laboratory Revenue + Industrial Revenue + Retail Revenue
- COGS = Total Revenue x (1 - Gross Margin Percentage)
- R&D Expense = Total Revenue x R&D Margin Percentage
- SG&A Expense = Total Revenue x SG&A Margin Percentage
- Operating Income = Total Revenue - COGS - R&D Expense - SG&A Expense
- Free Cash Flow = Operating Cash Flow - Capital Expenditures
- Share Repurchases = Free Cash Flow - Minimum Cash Balance Requirement + Net Debt Issuance
- Ending Shares Outstanding = Beginning Shares Outstanding - (Share Repurchases / Average Share Price)
- EPS = Net Income / Ending Shares Outstanding
Cross-Sheet Dependencies
- The Revenue_Build sheet feeds the top line of the Income_Statement and drives the activity levels in the Working_Capital sheet.
- The Income_Statement generates Net Income, which is the starting point for the Cash_Flow_Statement.
- The Working_Capital sheet calculates changes in operating assets and liabilities, feeding the Cash_Flow_Statement.
- The Cash_Flow_Statement determines the cash available for share repurchases, which feeds the Shareholders_Equity sheet and reduces the share count on the Income_Statement for EPS calculations.
- Circularity risk: Interest expense on the Income_Statement depends on the debt balance on the Debt_and_Interest sheet, which depends on the cash shortfall/surplus from the Cash_Flow_Statement, which in turn depends on Net Income. A circuit breaker toggle is required.
Sign Convention
- Revenue and Asset balances are positive.
- Expenses (COGS, R&D, SG&A) are entered as positive numbers in their respective build schedules but subtracted in the Income Statement totals.
- Liability and Equity balances are positive.
- Cash inflows on the Cash Flow Statement are positive; cash outflows (including Capex and Share Repurchases) are negative.
Things Most Likely to Go Wrong
- Failing to account for the aggressive share reduction: MTD's EPS grows much faster than Net Income because of constant buybacks. The model must dynamically reduce share count.
- Overestimating capital intensity: MTD is highly asset-light. Modelling capex too high will severely understate Free Cash Flow.
- Ignoring foreign exchange impacts: MTD reports in USD but generates over 50% of revenue in Europe and Asia. The model should ideally evaluate constant currency growth rates.
- Mismodelling gross margins: Tariffs and freight costs can swing gross margins by 50 to 100 basis points, which has a massive impact on operating profit due to low variable costs.
- Overcomplicating the service revenue: MTD does not report Service as a standalone segment; it is embedded within Lab, Industrial, and Retail. Do not try to build a separate Service segment on the Income Statement.
- Missing discrete tax benefits: MTD frequently reports non-cash discrete tax benefits (e.g., $0.95 per share in 2025). The effective tax rate should be normalised for forecasting.
- Misunderstanding working capital: MTD operates with very tight, sometimes negative, working capital. Do not assume standard industry DSO/DIO ratios without checking historicals.
- Ignoring shipping delays: Quarter-to-quarter revenue can be lumpy due to logistics provider issues. Focus on annualised trends.
Validation Checks
- Gross margin must remain between 58.0% and 61.0%.
- Operating margin should be in the 29.0% to 31.0% range.
- Free Cash Flow conversion (FCF / Net Income) must be >100%.
- Capex as a percentage of revenue should not exceed 3.5%.
- Debt to EBITDA should remain below 2.5x.
- Total Assets must equal Total Liabilities plus Shareholders' Equity in all periods.
- Share count must decrease year-over-year if Free Cash Flow is positive.
- Effective tax rate should remain between 17.0% and 19.0% excluding discrete items.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Laboratory Instruments Growth | 4.0 | % | Reflects normalised growth in bioproduction and pharma R&D |
| Industrial Instruments Growth | 3.0 | % | Aligns with long-term industrial automation trends |
| Retail Weighing Growth | 1.0 | % | Mature market with slow replacement cycles |
| Gross Margin | 59.5 | % | Blended average reflecting recent tariff pressures and pricing power |
| R&D as % of Revenue | 4.8 | % | Consistent historical investment in software and digital sensors |
| SG&A as % of Revenue | 25.5 | % | Reflects the cost of maintaining a massive global direct sales force |
| Effective Tax Rate | 18.0 | % | Normalised rate excluding one-time discrete tax benefits |
| Capex as % of Revenue | 2.8 | % | Asset-light manufacturing footprint |
| DSO | 40 | Days | Based on historical receivables performance |
| DIO | 45 | Days | Based on historical inventory management |
| DPO | 40 | Days | Based on historical supplier payment terms |
| Share Repurchase % of FCF | 95.0 | % | Management consistently returns almost all FCF via buybacks |
| Cost of Debt | 4.5 | % | Weighted average interest rate on senior notes and revolver |
| WACC | 8.5 | % | Standard discount rate for a stable, large-cap precision instruments firm |
| Terminal Growth Rate | 3.0 | % | Aligns with long-term global GDP and inflation expectations |
Data Sources & Benchmarks
- SEC EDGAR: Mettler-Toledo International Inc. (MTD) 10-K and 10-Q filings.
- Investor Relations: mt.com/investors for earnings presentations and transcripts.
- Key Peers: Waters Corporation (WAT), Agilent Technologies (A), Thermo Fisher Scientific (TMO), PerkinElmer (PKI).
- Industry Data: Global manufacturing PMIs, pharmaceutical R&D spending reports.
- Consensus Estimates: FactSet or Bloomberg for forward-looking EPS and revenue estimates.
Sources
- Mettler-Toledo International Inc. 2024 and 2025 Annual Reports (Form 10-K)
- Mettler-Toledo Q4 2025 Earnings Press Release and Financial Schedules
- SEC EDGAR Database
- Mettler-Toledo Investor Relations Website
- Motley Fool: Mettler-Toledo International Stock Price & News
- Seeking Alpha: Mettler-Toledo International Earnings Analysis
Do more with the Mettler Toledo model
Frequently asked
What does Mettler Toledo do?+
Mettler Toledo is a global manufacturer of precision instruments and services for use in laboratory, industrial, and food retailing applications. The company also generates significant recurring revenue from its global service network, which accounts for approximately 25% of total sales.
What are Mettler Toledo's main revenue streams?+
Mettler Toledo's revenue is primarily driven by its Laboratory Instruments segment, which accounts for approximately 56% of revenue, and Industrial Instruments, contributing about 39%. A significant portion of its total sales, around 25%, comes from recurring service revenue due to its massive installed base and global service network.
What is Mettler Toledo's capital expenditure strategy?+
Mettler Toledo operates an asset-light business model, with capital expenditure typically ranging from 2.5% to 3.5% of revenue. This capex is roughly split between maintenance and growth, with growth investments focusing on IT infrastructure, software development, and facility automation.
What is the purpose of the Mettler Toledo financial model?+
The Mettler Toledo financial model projects the company's three-statement financials and free cash flow. Its primary purpose is to determine MTD's intrinsic equity valuation and evaluate the sustainability of its aggressive share repurchase program.
Can I download an Excel financial model for Mettler Toledo?+
Yes, an Excel financial model for Mettler Toledo (MTD) is available for download. This model projects the company's financials from FY2026 to FY2030 and includes key assumptions for revenue growth, margins, and capital expenditures.
How does Mettler Toledo maintain its market position and profitability?+
Mettler Toledo holds the global number-one market position in most of its product categories, benefiting from high switching costs for customers. This, combined with a massive installed base, drives a significant recurring service revenue stream, contributing to its highly profitable and asset-light business model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Laboratory Equipment Company Financial Models
Browse another company in the same sector.
Agilent Technologies
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing application-focused solutions that include instruments, software, services, and consumables for the entire laboratory workflow.
Danaher
Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services.
Revvity
Revvity provides health science solutions, technologies, and services spanning discovery, development, and diagnosis, offering instruments, reagents, and informatics software through its Life Sciences and Diagnostics segments, including newborn screening platforms.
Bio-Techne
Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells bioactive reagents, analytical instruments, and precision diagnostics for the research and clinical diagnostic markets.
Thermo Fisher Scientific
Thermo Fisher Scientific is the world's largest supplier of scientific instrumentation, reagents, consumables, and software to life sciences, clinical, and industrial laboratories.
Waters
Waters Corporation designs, manufactures, sells, and services analytical instruments, primarily liquid chromatography and mass spectrometry systems.
Explore more Healthcare financial model templates.
